Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Conditions:   Fallopian Tube Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Recurrent Fallopian Tube Clear Cell Adenocarcinoma;   Recurrent Fallopian Tube Endometrioid Adenocarcinoma;   Recurrent Fallopian Tube Transitional Cell Carcinoma;   Recurrent Fallopian Tube Undifferentiated Ca rcinoma;   Recurrent High Grade Fallopian Tube Serous Adenocarcinoma;   Recurrent High Grade Ovarian Serous Adenocarcinoma;   Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma;   Recurrent Low Grade Ovarian Serous Adenocarcinoma;   Recurrent Ovarian Clear Cell Adenocarcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Ovarian Mucinous Adenocarcinoma;   Recurrent Ovarian Transitional Cell Carcinoma;   Recurrent Ovarian Undifferentiated Carcinoma;   Recurrent Platinum-Resistant Fallopian Tube Carcinoma;   Recurrent Platinum-Resistant Ov arian Carcinoma;   Recurrent Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Primary Peritoneal Clear Cell Adenocarcinoma;   Recurrent Primary Peritoneal Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Primary Peritoneal Lo w Grade Serous Adenocarcinoma;   Recurrent Primary Peritoneal Transitional Cell Carcinoma;   Recurrent Primary Peritoneal Undifferentiated Carcinoma Interventions:   Drug: Cediranib Maleate;   Biological: Durvalumab;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated L...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials